{"id":3616321,"date":"2023-07-11T17:42:56","date_gmt":"2023-07-11T21:42:56","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/?post_type=story&p=3616321"},"modified":"2023-07-11T17:50:32","modified_gmt":"2023-07-11T21:50:32","slug":"podcast-why-neuroscience-is-the-final-frontier","status":"publish","type":"story","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/stories\/podcast-why-neuroscience-is-the-final-frontier\/","title":{"rendered":"Podcast: Why neuroscience is the \u2018final frontier\u2019"},"content":{"rendered":"\n
\n
\n \n \n Innovation<\/small>\n <\/a>\n \n \n

\n Podcast: Why neuroscience is the \u2018final frontier\u2019\n <\/h1>\n

Listen as specialists from Merck discuss what they\u2019re most excited about in researching potential treatments for neurologic disorders<\/p>\n <\/div>\n\n

\n

July 11, 2023<\/p>\n

\n

Share this article<\/p>\n

\n \nFacebook icon<\/title><\/svg>\n<\/a><\/p>\n

\n\n\n\n\t.st0{fill:#00857C;}\n\n\nX icon<\/title><\/svg>\n<\/a><\/p>\n

\n \nLinkedin icon<\/title><\/svg>\n<\/a><\/p>\n

\n \nEmail icon<\/title><\/svg>\n<\/a><\/p>\n <\/div>\n <\/div>\n\n
\n
\n
\n \n \n \n \n \"Four\n <\/picture>\n\n <\/figure>\n \n <\/div>\n <\/div>\n\n
\n
\n
\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n\n\n\n

Our scientists are revolutionizing how we discover and develop treatments to address unmet medical needs in a number of areas, including neuroscience.<\/p>\n\n\n\n

\u201cIt’s sort of like the final frontier,\u201d said Joe Herring, scientific AVP, clinical research, in our new podcast. \u201cYou’re going off into space to try to figure out how to do very difficult things.\u201d<\/p>\n\n\n\n

For more, listen in as Herring sits down with Merck clinical research team senior principal scientists Yuki Mukai and Ari Merola as well as business development director Paige Lacatena to explore today\u2019s breakthroughs and challenges in the field of neuroscience.<\/p>\n\n\n\n

Listen to the podcast<\/h2>\n\n\n\n